Retatrutide — compounding legality overview

Emerging GLP-1 triple agonist

Common names: LY3437943

PeptSense tracks Retatrutide across federal 503A Bulks List chain steps, PCAC advisory context, and state board positions. Status is never inferred from forums or marketing sites — only published citations with effective dates.

Federal 503A snapshot (illustrative)

Latest published federal event for 503A compounding pharmacies. Sign in for your licensed states and facility type.

Summary

Honest curation baseline (2026-08-01): no clear published 503A Bulks List inclusion identified for Retatrutide in this pass. Status under_review pending deeper FR / nomination review. Not a legal determination.

Citation

FDA — 503A bulk drug substances / compounding hub

Effective

Aug. 1, 2026

Not a legal determination. Replace placeholder citations during curation.

Run a full lookup

Get federal + state lanes, chain steps, printable answer cards, and compliance documents for the states you license in.